Influence of apoptosis and cell cycle regulator proteins on chemotherapy response and survival in stage IIIA/IIIB NSCLC patients

Journal of Thoracic Oncology

Volumn 2, Issue 4, 2007, Pages 293-298

  Morero, José L ^a   Poleri, Claudia ^a,b   Martín, Claudio ^a   Van Kooten, Maximiliano ^a   Chacón, Reynaldo ^a   Rosenberg, Moisés ^a  

^a Hospital Maria Ferrer   (Argentina)

^b NONE   (Argentina)

Author keywords

Apoptosis; Non small cell lung cancer

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GEMCITABINE; KI 67 ANTIGEN; NAVELBINE; PACLITAXEL; PROTEIN BCL 2; PROTEIN P53; REGULATOR PROTEIN; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; TUMOR MARKER;

ADULT; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; ADJUVANT THERAPY; AGED; ANALYSIS OF VARIANCE; BLOOD; DRUG EFFECT; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; PROBABILITY; RISK ASSESSMENT; SURVIVAL; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROBABILITY; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34247857604     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000263711.54073.fa     Document Type: Article

References (31)

1. Mountain CF. Revision in the International System for staging Lung Cancer. Chest 1997;11:1710-1717.
2. Roth JA, Fossella F, Komaki R, et al. A randomised trial comparing perioperative chemotherapy and surgery with surgery alone in resectable IIIA NSCLC. J Natl Cancer Inst 1994;86:673-680.
3. Rosell R, Gómez-Codina J, Camps C, et al. A randomized trial comparing pre operative chemotherapy plus surgery with surgery alone in patients with non small cell lung cancer. NEJM 1994;330:153-158.
4. CHEST guidelines for treatment of stage IIIA non small cell lung cancer. Chest 2003;123:202-220.
5. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resected stage I (except T1N0), II, and IIIA NSCLC. J Clin Oncol 2002;20:247-253.
6. Massion P, Carbone D. The molecular bases of lung cancer: molecular abnormalities and therapeutic implications. Respir Res 2003;4:12-27.
7. Huang C, Liu D, Masuya D, et al. Clinical application of biological markers for treatment of resected NSCLC. Br J Cancer 2005;92:1231-1239.
8. Steels E, Paesmans B, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of literature with a meta-analysis. Eur Respir J 2001;18:705-719.
9. Brundage M, Davies D, Makilliop W. Prognostic factor in non small cell lung cancer: a decade of progress. Chest 2002;122:1037-1057.
10. Zhu C-Q, Shih W, Ling C-H, Tsao M-S. Immunohistochemical markers of prognosis in non small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006;59:790-800.
11. Weiss R. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003;4:425-429.
12. Rubio L, Vera-Sempere JA, López-Guerrero Padilla J, Moreno-Baylach MJ. A risk model for non small cell lung cancer using clinicopathological variables, angiogenesis and oncoprotein expression. Anticancer Res 2005;25:497-504.
13. Kwon MS, Lee YI, Lee K. p21 as a prognostic factor in Non Small Lung Carcinomas. Pathology 2006;202:849-856.
14. Fokkema E, Timens W, de Vries E, et al. Expression and prognostic implication of apoptosis-related proteins in locally unresectable non-small cell lung cancers. Lung Cancer 2006;52:241-247.
15. Toyooka S, Tsuda T, Gazdar A. The Tp53 Gene, Tobacco Exposure, and Lung Cancer. Hum Mutat 2003;21:229-239.
16. Tsihlias J, Kapusta L, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 1999;50:401-23.
17. Poleri C, Morero JL, Nieva B, et al. Risk of recurrence in patients with surgically resected stage I non- small cell lung carcinoma. Histopathological and immunohistochemical analysis. Chest 2003;123:1858-1867.
18. Trodella L, Granone P, Valente S, et al. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) NSCLC: long term results according to downstaging. Ann Oncol 2004;15:389-398.
19. Machtay M, Lee J, Stevenson J, et al. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non small cell lung carcinoma: long-term results and association with pathologic response. J Thorac Cardiovasc Surg 2004;127:108-113.
20. Shoji T, Tanaka F, Takata T, et al. Clinical significance of p21 expression in non small cell lung cancer. J Clin Oncol 2002;20:3865-3871.
21. Gartel A, Radhakrishnan S. Lost in transcription: p21 repression, mechanisms and consequence. Cancer Res 2005;65:3980-3985.
22. Gartel A, Tyner A. The role of cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002;1:639-649.
23. Fan S, Chang J, Smith M, Duva D, Fornase A, O'Connor P. Cells lacking Cip1Waf1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene 1997;14:2127-2136.
24. Wang D, Lippard S. Cellular processing of platinum anticancer drug. Nat Rev 2005;4:307-319.
25. Bearss D, Lee R, Troyer D, Pestell R, Windle J. Differential effects of p21WAF1/CIP1 deficiency on MMTV-ras and MMTV-myc mammary tumor properties. Cancer Res 2002;62:2077-2084.
26. Tanaka F, Yanaghiara K, Otake Y, et al. Prognostic factor in resected pathologic (p-) stage IIIA-N2, non small cell lung cancer. Ann Surg Oncol 2004;11:612-618.
27. Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF. Apoptosis and lung cancer: a review. J Cell Biochem 2003;88:885-898.
28. Tanaka F, Kawano Y, Li M, et al. Prognostic significance of apoptotic index in completely resected non-small-cell lung cancer. J Clin Oncol 1999;19:2728-s736.
29. Staunton MJ, Gaffney EF. Apoptosis. Basic concepts and potential significance in human cancer. Arch Pathol Lab Med 1998;122:310-319.
30. Dworakowska D, Jassem E, Jassem J, et al. Clinical significant of apoptotic index in non small cell lung cancer: correlation with p53, mdm2, p Rb and p21 Waf1Cip1 protein expression. J Cancer Res Clin Oncol 2005;131:617-623.
31. Geske FJ, Gerschenson LE. The biology of apoptosis. Hum Pathol 2001;32:1029-1038.